{"id":"W2884876277","doi":"10.1158/1078-0432.ccr-18-0981","title":"Randomized Phase II Study Evaluating Akt Blockade with Ipatasertib, in Combination with Abiraterone, in Patients with Metastatic Prostate Cancer with and without PTEN Loss","year":2018,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":310,"is_retracted":false,"has_abstract":true,"ca_institutions":"Institute of Cancer Research","funders":"Genentech; F. Hoffmann-La Roche","keywords":"PTEN; Prostate cancer; Medicine; Abiraterone; Blockade; Oncology; Cancer; Randomized controlled trial; Prostate; Internal medicine; Metastatic breast cancer; PI3K/AKT/mTOR pathway; Breast cancer; Androgen receptor; Biology; Receptor; Apoptosis","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"randomized_trial","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low","status":"direct model label, unvalidated"},{"model":"gpt","categories":[],"domain":null,"study_design":"randomized_trial","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"high","status":"direct model label, unvalidated"}],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002154397,0.001700718,0.002513135,0.0003481476,0.0004461276,0.001219381,0.000999647,0.001823252,0.005075138],"category_scores_gemma":[0.002147299,0.0008586522,0.001806342,0.0005992576,0.001210996,0.001159537,0.0004109672,0.00463127,0.0009804943],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001011844,"about_ca_system_score_gemma":0.001885409,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009693649,"about_ca_topic_score_gemma":0.00280578,"domain_scores_codex":[0.9992549,0.0004211355,0.00004467298,0.0001253678,0.00005650858,0.00009745638],"domain_scores_gemma":[0.9986936,0.0003044218,0.0002712769,0.0001092231,0.00009626872,0.0005251074],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9543137,0.01457104,0.001365846,0.0003785612,0.001362748,0.00008519387,0.00007848786,0.0004823092,0.007090077,0.0001707608,0.00201039,0.01809084],"study_design_scores_gemma":[0.9063851,0.09006647,0.001337447,0.00001481255,0.0004090894,0.00004896757,0.00001725916,0.0002698657,0.0004230556,0.0001315284,0.000884828,0.00001168846],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9743248,0.005508968,0.00168877,0.002678046,0.001121165,0.007725731,0.002864922,0.0002307829,0.003856808],"genre_scores_gemma":[0.9766168,0.003161071,0.002644511,0.003061005,0.0007875558,0.006638476,0.002711411,0.00005945075,0.00431974],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005075138,"threshold_uncertainty_score":0.01697797,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1848900057240528,"score_gpt":0.5496204690412394,"score_spread":0.3647304633171866,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}